AnanthJ. V., BanT. A., and LehmannH. E.: Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics.Can. Psychiatr. Assoc. J., 18: 5, 377–383, 1973.
2.
AnanthJ. V., BanT. A., LehmannH. E., and BennettJean: Nicotinic acid in the prevention and treatment of methionine-induced exacerbation of psychopathology in schizophrenic patients.Can. Psychiatr. Assoc. J., 15: 1, 15–19, 1970.
3.
AnanthJ. V., VacaflorL., KekhwaG., SterlinC., and BanT. A.: Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo controlled study.Int. J. Clin. Pharmacol., 5: 406–410, 1972.
4.
HofferJohn: The controversy over ortho-molecular therapy.Journal of Orthomolecular Psychiatry, 3: 18–36, 1974.
5.
ParsonsWilliam B.Jr., and FlinnJohn H.: Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid.Arch. Intern. Med., 103: 783–790, 1959.
6.
WittenbornJ. R., WeberE. S. P., and BrownM.: Niacin in the long-term treatment of schizophrenia.Arch. Gen. Psychiatry, 28: 308–315, 1973.
7.
WittenbornJ. Richard: A search for responders to niacin supplementation.Arch. Gen. Psychiatry, 31: 547–552, 1974.
